Dept. of Justice to probe Plavix settlement

FBI agents raided the office of Bristol-Myers Squibb CEO Peter Dolan late last week as part of a criminal probe into the deal the company struck to stave off generic competition for its top-selling Rx drug product, the blood thinner Plavix. The probe concerns a settlement reached in March between Bristol, Plavix marketing partner Sanofi-Aventis and the generic drugmaker Apotex. Under the deal, Apotex, which received FDA approval to market a generic version of Plavix in March, said it would not begin selling its copycat version of the drug until 2011. The deal last week failed to receive required antitrust clearance from the US state attorneys general. Plavix accounts for 30% of Bristol's profits with global sales of over $5 billion, making it one of the world’s top three best-selling prescription drugs.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.